MedTrace Logo

ToleroMune Ragweed Exposure Chamber Study

NCT01198613 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2011-10-07

No results posted yet for this study

Summary

It is believe that ragweed is the primary cause of autumn allergies and 87% of patients with ragweed allergy suffer rhinoconjunctivitis. ToleroMune Ragweed is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of ragweed allergy.

This study will look at the efficacy, safety and tolerability of two doses of ToleroMune Ragweed in ragweed allergic subjects following challenge with ragweed in an EEC.

Conditions

  • Ragweed Allergy

Interventions

BIOLOGICAL

ToleroMune Ragweed

Intradermal injection 1 x8 administrations 2 weeks apart

BIOLOGICAL

Placebo

Intradermal injection, 1x8 administrations 2 weeks apart

Sponsors & Collaborators

  • Adiga Life Sciences, Inc.

    collaborator INDUSTRY

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Deepen Patel, MD, CCFP · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01198613 on ClinicalTrials.gov